Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors

Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors www.nature.com/scientificreports Correction: Author Correction OPEN Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors Received: 30 May 2017 1 1 2 1,2 Julia S. Martin del Campo , Meital Eckshtain-Levi , Nancy J. Vogelaar & Pablo Sobrado Accepted: 17 August 2017 Aspergillus fumigatus is an opportunistic human pathogen responsible for deadly, invasive infections Published: xx xx xxxx in immunocompromised patients. The A. fumigatus cell wall is a complex network of polysaccharides among them galactofuran, which is absent in humans. UDP-galactopyranose mutase (UGM) catalyzes the conversion of UDP-galactofuranose (UDP-Galf) to UDP-galactopyranose (UDP-Galp) and is an important virulence factor. UGM is a flavin-dependent enzyme that requires the reduced flavin for activity; flavin reduction is achieved by reaction with NADPH. The aim of this work was to discover inhibitors of UGM by targeting the NADPH binding site using an ADP-TAMRA probe in a high- throughput screening assay. The flavonoids (2S)-hesperetin and (2S)-naringenin were validated as competitive inhibitors of UGM against NADPH with K values of 6 µM and 74 µM, respectively. To gain insight into the active chemical substituents involved in the inhibition of UGM, several derivatives of these inhibitors were studied. The results show that the hydroxyl groups of (2S)-hesperetin are important for inhibition, in particular the phenyl-chroman moiety. Congo red susceptibility assay and growth temperature effects showed that these compounds affected cell wall biosynthesis in A. fumigatus. This work is the first report of inhibition studies on UGM from eukaryotic human pathogens. Aspergillus fumigatus is a common opportunistic human pathogen that causes infections such as allergic bron- 1,2 chopulmonary aspergillosis and invasive pulmonary aspergillosis, among others . Patients with acute leukemia, hematopoietic stem cell transplant recipients, and solid-organ transplant recipients are the three most common groups of patients at risk of invasive A. fumigatus infections . Although drugs are available for treating A. fumiga- tus infections, the mortality rate among immunocompromised persons is >50% . The fungal cell wall is essential to maintaining cell integrity and plays an important role in host-pathogen interactions. Several cell wall compo- nents are fungal specific and absent in mammals . The cell wall of A. fumigatus consists of a three-dimensional arrangement of polysaccharides. The central core is composed of branched β−1,3-glucan cross-linked to chitin. The external core of the cell wall is composed of glucose chains of β -1,3–1,4 glucan and galactomannan, which makes the structure unique compared to other fungi . Galactomannans are the major antigens produced during infection by A. fumigatus and possibly act as components of extracellular adhesive structures during host tissue invasion . Secreted galactomannan is composed of a branched core containing α(1 → 2)- and α(1 → 6)-linked mannose, with β(1 → 5)-galactofuranose and/or β(1 → 4)-galactopyranose moieties linked linearly in side chains 7,10,11 terminated by galactofuranose non-reducing end units (Fig. 1a). Galactofuranose (Galf) is a five-member cyclic hexose found in several pathogens but is absent in humans. The synthesis of Galf starts in the cytosol where UDP-galactopyranose (UDP-Galp) is transformed to UDP-Galf by UDP-galactofuranose mutase (UGM, Fig. 1b). UGM is a key enzyme in the biosynthesis of galactofuranose containing glyco-conjugates. Deletion of A. fumigatus UGM prevents Galf production and results in a strain with reduced cell wall thickness and attenuated virulence in mice . In addition, UGM has been shown to be essential for the pathogenesis of Mycobacterium 13 14,15 tuberculosis and for larval hatching and long-term survival of the nematodes Brugia malayi and Caenorhabditis elegant . In the protozoan pathogen Leishmania major, UGM has also been identified as a vir - ulence factor . UGM is a flavoenzyme that catalyzes a non-redox reaction; however, the flavin is required to be in the reduced form for catalysis . The catalytic cycle of UGM starts with NADPH binding, then reduction of the FAD occurs and, finally, release of NADP (Fig. 1b,i–iii). UDP-Galp binds to the reduced UGM (Fig. 1b,iv) and the chemical steps are initiated by nucleophilic attack of the FAD N5 atom to the Galp C1 atom, generating 1 2 Department of Biochemistry, Virginia Tech, Blacksburg, VA, 24061, USA. Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA, 24061, USA. Correspondence and requests for materials should be addressed to P.S. (email: psobrado@vt.edu) SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 1 www.nature.com/scientificreports/ Figure 1. (a) Depiction of secreted galactomannan showing the (1 → 5)-linked Galf chains bound to mannose units (M). (b) Chemical mechanism for UGM. The activation of UGM by NADPH is depicted in i and ii. The reduced activated enzyme (iii), binds to UDP-Galp and a covalent flavin–galactose adduct is formed via the direct attack of the FAD-N5 atom to the Galp-C1 atom. This step leads to cleavage of the anomeric bond (iv-v). Tautomerization of the flavin permits the transfer of the FAD-N5-proton (shown in red) to the C4FAD = O (vi). This proton is next transferred to the Galp-C5-O, facilitating the opening of the sugar ring and formation of the flavin iminium ion (vi-vii). The FAD-C4 = O is predicted to accept the proton from the Galp-C4-OH (shown in blue) during ring contraction (viii). The final step is the direct attack of UDP to the FAD–galactofuranose adduct (ix-x). a flavin-Galp intermediate (Fig. 1b,iv–v). Formation of a flavin-sugar iminium ion leads to opening of the sugar ring (Fig. 1b,vi–vii). After recyclization, attack by UDP releases the sugar of the flavin and forms the product, UDP-Galf (Fig. 1b,viii–x) . UGMs can react with molecular oxygen leading to the oxidation of the flavin, which is the inactive form of the enzyme (Fig. 1b,i). FAD oxidation occurs very slowly aer ft following several hundred mutase reactions . Crystallographic data showed that the ADP group of NAD(P)H and the UDP group of the substrate have independent binding pockets, while the nicotinamide riboside binding site overlaps with the binding of the Galp 19,21 moiety in order to access the flavin N5 atom . The unique arrangement of the NAD(P)H binding domain of UGM represents an attractive target for the design of inhibitors of the oxidized (inactive) enzyme that bind in the pocket, which is unique to the ADP component of NADPH. In this work, a 2320 compound library was screened against oxidized A. fumigatus UGM using a TAMRA labeled ADP (ADP-TAMRA) . The flavonoids (2S )-hesperetin and (2S)-naringenin were identified as compet- itive inhibitors against NADPH. Binding of inhibitors caused an increase in the melting temperature of UGM (~2.7 °C). Inhibition studies of (2S)-hesperetin derivatives allowed us to identify the hydroxyl group of the phenyl-chroman moiety as essential for binding and inhibition. In cultures of A. fumigatus, (2S)-hesperetin and (2S)-naringenin increased thermosensitivity and susceptibility to the cell wall stressing agent congo red. This work represents the first efforts in inhibitor discovery against eukaryotic UGM. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 2 www.nature.com/scientificreports/ Figure 2. (a) HTS against UGM using ADP-TAMRA (30 nM). (b) Funnel diagram illustrating the processes of inhibitor identification and validation. Results High-throughput screening assay and hit validation. Previously, our group developed an ADP- TAMRA probe to identify inhibitors of flavin-dependent monooxygenases that use NADPH as a substrate . To determine the utility of ADP-TAMRA to search for inhibitors of recombinant A. fumigatus UGM (UGM, from here on), ADP-TAMRA binding was tested as a function of UGM concentration. The observed increase in the anisotropy as a function of UGM concentration permitted the calculation of a K value of 6.7 µ M (Fig. S1a). Competitive binding of ADP or NADP against ADP-TAMRA (Fig. S1b) was confirmed from the K value of the UGM-chromophore complex (anisotropy value of ~0.18) upon addition of increasing concentrations of either ligand. Thus, the change in anisotropy, upon release of ADP-TAMRA from the active site of UGM was used as the signal for a high-throughput screening (HTS) assay to identify small compounds that bound to UGM. Using this HTS assay, the Spectrum Collection library (2320 compounds) was screened against UGM at 20 µ M concentra- tion (2% DMSO) as described in the methods section. The Spectrum library was selected because of its diverse composition of bioactive compounds (60%), natural compounds of unknown biological properties (25%), and compounds representative of known drug-enzyme inhibitors, among others. It is known that aggregate-based inhibition is time dependent . In order to remove aggregators from screen- ing, we measured the anisotropy after incubation at 30 min and 120 min. The die ff rence between the two-time point readings was used to assess aggregation. Compounds with absolute difference in anisotropy between read- ings that was greater than 12% (corresponding to 3 standard deviations of the negative control) were considered aggregators and not studied further, leaving 2130 compounds (Fig. 2a). The average Z′ factor was calculated to be 0.82 ± 0.04, which indicates a wide separation between positive and negative controls. Hits were defined as compounds that had an anisotropy ≤ 50% at 30 min incubation (Fig. 2b). From the 26 identified hits, compounds that oxidized NADPH were removed. Only 13 compounds were commercially available and they were classified as flavonoids and non-flavonoids (Table S1). Inhibition of product formation followed by UPLC at 20 and 200 µ M compound concentration in 2% DMSO allowed for the identification of five compounds that exhibited a concentration dependent potency: (2S)-hesperetin, (2S)-naringenin, and chrysin from the flavo- noid family, and diclazuril and febuxostat from the non-flavonoid family. The melting temperature of UGM (meas- ured with the ThermoFAD method) with 20, 100, and 1000 µ M of compound (2% DMSO and 1 mg/mL UGM) indicated that diclazuril and febuxostat are UGM denaturants, as these compounds reduced the T compared to the reference (UGM alone in 2% DMSO) and were not further studied. Chrysin showed no effect on T and (2S)-hesperetin and (2S)-naringenin increased the T by ~2.7 °C. The positive shift in T caused by (2S)-hesperetin m m and (2S)-naringenin (Fig. S2) is comparable to the effect of 10 mM UDP, which causes a shift of 3 °C. Determination of IC , K values, and the mechanism of inhibition of UGM inhibitors. IC val- 50 D 50 ues were determined with the UPLC method using sodium dithionite as the reducing agent (Fig. 3a,b). Chrysin showed the highest potency followed by (2S)-hesperetin and (2S)-naringenin (Table 1). However, the IC curve of chrysin saturated below full enzyme inhibition (~35% activity, ~30 µ M chrysin), and precipitated above 100 µ M (with 2% DMSO). These behaviors agree with the reported mechanism that involves the formation of a colloidal aggregate by the compound, which precipitates as the concentration rises . As expected, chrysin did not inhibit NADPH oxidation, nor was binding detected with ITC. The IC for (2S)-hesperetin and (2S)-naringenin was also determined by following NADPH oxidation by UGM in the absence of UDP-Galf (Fig. 3c,d). It was found that (2S)-hesperetin and (2S)-naringenin inhibited NADPH oxidation. The type of inhibition by (2S)-hesperetin and (2S)-naringenin was assessed with the NADPH oxidation assay at different concentrations of inhibitor. (2S)-Hesperetin and (2S)-naringenin were competitive against NADPH. The K values for (2S)-hesperetin and (2S)-naringenin were 6 ± 1 µ M and 74 ± 24 µ M, respectively. The K for all ligands was determined by ITC meas- urement. The K values for (2S)-hesperetin and (2S)-naringenin were higher than that for NADP and lower than that for UDP (Fig. 4 and Table 2). Interestingly, the binding of NADP , (2S)-naringenin, and (2S)-hesperetin was SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 3 www.nature.com/scientificreports/ Figure 3. Characterization of UGM inhibitors. IC curves obtained with UPLC activity assay for (a) (2S)- hesperetin and (b) (2S)-naringenin. IC curves for (c) (2S)-hesperetin and (d) (2S)-naringenin obtained by following NADPH oxidation. Double reciprocal plots for the NADPH oxidation by UGM in the presence of (e) (2S)-hesperetin or (f ) (2S)-naringenin. IC (µM) Name Chemical Structure UPLC NADPH oxidation Type of Inhibition K (µM) (2S)-hesperetin 40 ± 3 32 ± 7 Competitive (NADPH) 6 ± 1 (2S)-naringenin 161 ± 11 233 ± 28 Competitive (NADPH) 74 ± 24 Chrysin 24 ± 4 >1 mM — — Table 1. Characterization of UGM inhibitors identified by HTS of the Spectrum library using ADP-TAMRA. IC was determined with 20 µM UDP-Galf (UPLC) and 10 mM sodium dithionite and for the NADPH oxidation was determined with 250 µM NADPH and no substrate. exothermic; the enthalpy driven binding of NADP , (2S)-naringenin, and (2S)-hesperetin could indicate the formation of hydrogen bonds along with conformation changes. While the entropy driven binding of UDP could be related to hydrophobic interaction and water release. Inhibition studies of (2S)-hesperetin and (2S)-naringenin derivatives. To characterize the structural components important for inhibition, commercially available derivatives of (2S)-hesperetin and (2S)-naringenin were studied. The selected compounds included modification in the phenyl moiety and/or in the dihydroxrychroman SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 4 www.nature.com/scientificreports/ Figure 4. Representative ITC results and fitting curves for substrates and inhibitors binding to UGM. (a) UDP and (b) NADP are shown for reference. (c) (2S)-hesperetin and (d) (2S)-naringenin. −1 −1 −1 Compound ∆G(kcal•mol ) ∆H(kcal•mol ) T•∆S(kcal•mol ) K (µM) UDP −7.1 ± 0.1 3.3 ± 0.1 10.5 ± 0.3 5.4 ± 0.8 NADP −4.6 ± 0.3 −13.0 ± 0.3 −8.4 ± 0.7 413 ± 24 (2S)-hesperetin −6.1 ± 0.4 −4.1 ± 0.4 2.1 ± 0.2 31 ± 6 (2S)-naringenin −5.7 ± 1.0 −4.8 ± 1.0 0.9 ± 0.3 65 ± 13 Table 2. er Th modynamic parameters for the ligands UDP, NADP and inhibitors binding to A. fumigatus UGM. moiety of (2S)-hesperetin as well as different hydroxychroman structures (Fig.  5a). (2S)-isosakuranetin was the only compound that inhibited the activity of UGM with an IC of 113 ± 9 µ M (UPLC assay, Fig. S3) and was not competitive with NADPH. The IC for (2S)-isosakuranetin is comparable to the IC of (2S)-naringenin. 50 50 (2S)-isosakuranetin increased the T of UGM by 1.3 ± 0.2 °C. This change in T is half the increase caused by m m (2S)-hesperetin and (2S)-naringenin (Fig. S2). No binding of (2S)-isosakuranetin to UGM was detected using ITC measurements. The structural difference between (2S )-hesperetin, (2S)-naringenin, and (2S)-isosakuranetin lies in the substituents of the phenyl group. In (2S)-hesperetin, the phenyl ring contains the 3-hydroxy-4-methoxy groups, while (2S)-naringenin and (2S)-isosakuranetin lack the 4-methoxy or the 3-hydroxy substituent, respectively. Modification in the 5,7-dihydroxrychroman-4-one moiety of (2S )-naringenin, specifically removing the 5-hydroxyl group of (2S)-naringenin, results in the compound liquiritigenin with no inhibitory effect against UGM. The R enan- tioniomer of naringenin and the dihydroxychroman derivatives showed no inhibition of UGM. Activity of UGM inhibitors in A. fumigatus cultures. We observed no A. fumigatus toxicity with (2S)-hesperetin and (2S)-naringenin at 1000 µ M in PDA medium at 37 °C (Fig. S4). We performed combined sus- ceptibility assays to congo red (0.5 and 1 mg/mL) with 100 µM (2S)-hesperetin and (2S)-naringenin. Aer 48 ft h of incubation at 37 °C we observed a growth decrease of ~50% and ~30% with (2S)-hesperetin and (2S)-naringenin respectively (Fig. 5b). When A. fumigatus was grown for 48 h at 50 °C in PDA with 1000 µ M (2S)-hesperetin or (2S)-naringenin, we observed a delay in colony development of ~50% and ~30% respectively when compared with the reference (Fig. S5). Discussion e ce Th ll wall of A. fumigatus is a complex and dynamic structure able to reprogram its composition to overcome genetic deficiencies and environmental stress . Current drugs against invasive and systemic A. fumigatus infec- tions include polyenes (e.g., amphotericin B), azoles (e.g., voriconazole), and echinocandins (e.g., caspofungin). Polyenes can bind to sterols and form pores in the cell membrane leading to increased membrane permeabil- ity. Azoles can block ergosterol biosynthesis causing an accumulation of lanosterol that reach toxicity levels. 27,28 Echinocandins are the only antifungals that target the cell wall by inhibiting β-1,3-glucan synthase . During infection, cell walls containing galactofuranose polysaccharides, specifically galactomannan, play important roles in host immune recognition . Secreted galactomannans in association with galactosamino- galactans are the major components of the biofilm mycelia found in aspergilomas and pulmonary lesions . UGM is a key enzyme in the biosynthesis of galactofuran-containing molecules and is a virulence factor in A. fumigatus . There are several research reports of inhibitors targeting the UDP-Gal p binding site of prokary- otic UGM. Recently, natural and synthetic flavonoids were reported as M. tuberculosis UGM inhibitors with a non-competitive mechanism of action . Different approaches to developing UGM inhibitors have been reported. These includes a cell-free enzymatic synthesis of UDP-Galf derivatives modified at C-5 and C-6, which pre- vent mycobacterial galactan polymerization . To date, there are no reports of inhibitors that target the unique NADPH binding site of UGM. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 5 www.nature.com/scientificreports/ Figure 5. (a) Structures of the (2S)-hesperetin and (2S)-naringenin derivatives studied in this work. (b) Susceptibility of A. fumigatus to congo red (0.5 mg/mL) and 100 µM (2S)-hesperetin and (2S)-naringenin. (c) Graphical depiction of the proposed attenuation strategy against A. fumigatus virulence. Inhibition of UGM traps it in its oxidized, or inactive, state and leads to the abolishment of UDP-Galf production and cell wall weakening. In this work, we reported that (2S)-hesperetin competitively inhibits UGM in its oxidized state by binding to the NADPH site and that (2S)-hesperetin is able to inhibit the conversion of UDP-Galf to UDP-Galp with an IC of 40 µ M. The potency of (2 S)-hesperetin is higher than the most recent report targeting the UDP-Galf binding site of UGM from M. tuberculosis where, exo-glycans bearing both a sulfone and a phosphonate irrevers- ibly inhibited UGM with an IC of 77 µ M . These two compounds, (2 S)-hesperetin and (2S)-naringenin, are flavonones found in citrus (orange and grapefruit). (2S )-Hesperetin is known to be an anti-inflammatory and 32 33 immunomodulatory agent . (2S)-hesperetin has shown cytoprotective activity in models of acute liver toxicity and has a protective effect against H O -induced oxidative damage in ARPE-19 cells . Nevertheless, it has been 2 2 reported that (2S)-hesperetin and (2S)-naringenin have an inhibitory effect on UDP-glucuronosyltransferases . Antimicrobial activities of (2S)-hesperetin include biofilm formation inhibition > 70% against S. aureus strains, where the formation of biofilm by S. aureus is associated with the synthesis of an extracellular β -1,6-linked N-acetyl (succinyl) glucosamine polymer . (2S)-Hesperetin and (2S)-naringenin were shown to be competitive inhibitors against NADPH, suggesting that these compounds bind to the active site of UGM. Thus, these compounds can prevent activation of UGM by blocking NADPH binding. Furthermore, these compounds effectively block the mutase activity of UGM as inhibition of chemically reduced UGM was also observed. It is possible that binding of flavonoids prevents 19,21 proper closing of the active site flaps and, thus, UDP binding . The thermodynamic behavior of the interaction SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 6 www.nature.com/scientificreports/ between UGM and (2S)-hesperetin and (2S)-naringenin resembles the binding of NADP , which is exothermic and enthalpy-driven. In contrast, the binding of UDP is endothermic and entropy-driven. Binding enthalpies between (2S)-hesperetin and (2S)-naringenin are not significantly different. Even so, the IC and K values of 50 i (2S)-hesperetin are about 10 times lower than for (2S)-naringenin. The discrepancy between binding enthalpies and inhibition constants could be a consequence of enthalpy gain compensated by entropy loss resulting from 37,38 strong hydrogen bonds between UGM and (2S)-hesperetin and, most likely, by the methoxy and hydroxy sub- stituents of the phenyl ring of (2S)-hesperetin. (2S)-Hesperetin and (2S)-naringenin have a stabilizing effect on UGM, increasing the melting temperature. e Th increased stability is attributed to a tighter conformation resulting from the binding of a small molecule. It has been reported that cell wall mutants are generally more sensitive to the anionic dye congo red, which interferes with the construction and stress response of the cell wall. The susceptibility to congo red is a response related to an increase in chitin deposition in the cell wall product of disturbed synthesis of β-1,3-glucan or β-1,6-glucan, mannosylation of mannoproteins, and glycosylphosphatidylinositol biosynthesis, among others . We observed an increased susceptibility to congo red in the presence of (2S)-hesperetin and (2S)-naringenin that could be related to changes in the galactomannan biosynthesis induced by partial UGM inhibition. Future crystallography studies of UGM with (2S)-hesperetin and (2S)-naringenin will allow design and optimization of more potent inhibitors of eukarytoic UGMs. Materials and Methods Materials. Buffers, antibiotics, and bacterial growth media were obtained from Fisher Scientific (Pittsburg, PA) and Sigma-Aldrich (St. Louis, MO). Turbo BL21 (DE3) chemically competent cells were obtained from Genlantis (San Diego, CA). For protein purification, an AKTA prime system (GE Healthcare) was used along with IMAC columns (GE Healthcare). Acquity ultraperformance liquid chromatography (UPLC) and Amide (1.7 µm, 2.1 mm × 100 mm) analytical columns were obtained from Waters (Milford, MA). NADPH was obtained from EMD Biosciences (Billerica, MA). UDP-Galf was synthesized as described previously . The Spectrum Collection library was purchased from Microsource (Gaylordsville, CT). For the FP assay, non-binding, surface black 384- well plates were purchased from Greiner Bio-One (Monroe, NC) and samples were analyzed on a Spectramax M5 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). Differential scanning fluorimetry was performed in an RT-PCR (Applied Biosystems 7300) using 96-well RT-PCR plates (Microamp 4306737) with optical adhesive films (MicroAmp 431197971). ITC measurements were performed in an Auto-ITC 200 from Malvern Instruments (Malvern, United Kingdom) and analyzed using the Microcal Origin version 7.0 from OriginLab (Northampton, MA). (2S)-Hesperetin was purchased from TCI America (Portland, OR) and (2S)- naringenin and (2S)-isosakuranetin from Fisher Scientic fi (Asheville, NC). (2 R)-naringenin was purchased from Vitas-M Laboratory (Champaign, IL). 5,7-dihydroxy-2,2-dimethylchroman-4-one was purchased from Hit2Lead (San Diego, CA). 7-hydroxychroman-4-one, 4-chroman, and liquiritigenin were purchased from ArkPharm (Arlington Heights, IL). Dehydrated potato dextrose agar was from BD Difco (Franklin Lakes, NJ) and Aspergillus fumigatus strain 46645 was purchased from the American Type Culture Collection (ATCC, Manassas, VA). Expression and purification of A. fumigatus UGM. UGM was expressed in the vector pVP55A as reported previously . Briefly, 6-L of terrific broth auto induction media containing 100 μg/ml ampicillin were inoc- ulated with 8 mL of overnight culture of BL21 Turbo cells transformed with the vector pPV55A and inoculated at 37 °C until an O.D. of 3 was reached. Then, the temperature was dropped to 18 °C and cultures were incubated for 18 additional hours. Cells were harvested by centrifugation at 5000 g for 20 min at 4 °C. The final wet-cell pellet (75 g) was stored at −80 °C. For protein purification, the cell paste was suspended in 250 mL of buffer A (25 mM HEPES, 300 mM NaCl, 25 mM imidazole, pH 7.5) and incubated with 25 mg/mL of lysozyme, DNAse I, and RNAse for 45 min at 4 °C with constant stirring. The resulting solution was sonicated in an ice bath for 15 min at 70% amplitude at cycles of 5S ON and 10S OFF. The lysate was centrifuged at 45,000 g for 45 min and the supernatant was collected and loaded onto three in-tandem 5 mL HisTrap columns previously equilibrated with buffer A. Aer lo ft ading was completed, the columns were washed with buffer A until the absorbance at 280 nm returned to baseline levels. UGM was eluted with Buffer B (25 mM HEPES, 300 mM NaCl, 300 mM imidazole, pH 7.5). To remove the 8× His-tag, the protein was dialyzed in the presence of 8× His-tobacco etch virus (8× His-Tev) protease (1:20 ratio) at 4 °C with slow stirring in buffer C (25 mM HEPES, 300 mM NaCl, pH 7.5). The dialyzed sample was loaded back onto the IMAC, previously equilibrated with buffer C, and the flow-through containing UGM was collected. The buffer of the purie fi d UGM was exchanged to 25 mM HEPES with 100 mM NaCl, a fl sh frozen, and stored at −80 °C until use. Binding of ADP-TAMRA to UGM and competition with NADP and UDP. Our group previously developed a binding assay to identify inhibitors of flavoenzymes that use NADP(H) as substrate. Since UGM also used NADPH for reduction, we determined whether this compound bound to UGM. This was done by taking the ADP-TAMRA chromophore to a final concentration of 30 nM in 25 mM HEPES buffer, pH 7.5, mixed with various concentrations of UGM (0–300 µ M, based on Bradford). To determine if the chromophore was binding to the active site of UGM, the competitive binding of UDP (0–1 mM) and NADP (0–10 mM) was calculated by measuring the decrease in anisotropy of the UGM (6.7 µ M) - ADP-TAMRA (30 nM) complex. At each concentra- tion of ligand, the solution was incubated for 10 min at room temperature. e s Th ample was excited at 544 nm and the emission recorded at 584 nm using a wavelength cutoff of 570 nm. High-throughput screening. High-throughput screening of the Spectrum Collection library using the FP assay with the ADP-TAMRA probe was performed at the Virginia Tech Center for Drug Discovery Screening Laboratory. 384 well plates (Greiner 784900) were used and the reaction volume was 15 µL using 25 mM HEPES SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 7 www.nature.com/scientificreports/ buffer (pH 7.0). For the screening, 30 nM of ADP-TAMRA with 6.7 µ M UGM (based on the Bradford assay) and 20 µ M of library compound were used, with a final DMSO concentration of 2%. Fluorescence polarization measurements were performed with excitation at 544 nm and emission at 584 nm, using a wavelength cutoff of 570 nm. Anisotropy measurements were performed aer 30 a ft nd 120 minutes of incubation at 25 °C. Anisotropy values were normalized to the values obtained in the negative control sample: UGM, ADP-TAMRA, and DMSO (high anisotropy values). The positive control consisted of ADP-TAMRA and DMSO (low anisotropy values). The Z prime (Z′) value was determined using equation (1) where, σ and μ represent the standard deviation and N,P N,P the mean value the of the negative and positive controls respectively. 3(σσ + ) NP Z′= 1 − μμ − (1) NP Hydrogen peroxide quantification assay. To identify compounds that oxidize NADPH, we screened the formation of hydrogen peroxide (H O ) in the absence of UGM using the xylenol orange assay as previously 2 2 reported . The assay was performed in 384 well plates (Greiner, 781162) and the reaction volume was 15 μL and consisted of 50 mM HEPES buffer (pH 7.5) containing 200 mM NaCl, 500 µ M NADPH, and 200 µ M of compound (dissolved in DMSO). The final DMSO concentration in the reaction mix was 2%. Controls contained 2% DMSO instead of compound. The reaction was started by the addition of NADPH and allowed to proceed at room tem- perature in the dark. Ae ft r 45 min, the reaction was quenched with 85 µ L of a freshly made solution of 200 mM sorbitol, 250 µ M xylenol orange, 500 µ M ammonium ferrous sulfate, and 25 mM sulfuric acid. Aer 10 ft minutes of incubation, the absorbance was measured at 595 nm. The concentration of H O in samples was determined by 2 2 comparison with a predetermined H O standard curve containing 2% DMSO. 2 2 ThermoFAD assays. The melting temperature of UGM was determined by measuring the FAD fluores- cence as a function of temperature (20–90 °C, 1 °C step) following the reported ThermoFAD procedure . The reaction mix consisted of 20 µ L of 1 mg/mL UGM, 2% DMSO in 50 mM potassium phosphate buffer, pH 7.0. As a reference and positive control, the T was calculated in the presence DMSO and UDP (10 mM). Different concentrations of inhibitors were added in the range of 0–1 mM at a final DMSO concentration of 2% in the above-mentioned buffer. All experiments were done in triplicate. Activity assay, IC , and K determination. e ac Th tivity of UGM and IC was determined by monitoring 50 i 50 the formation of UDP-Galp from UDP-Galf at 262 nm in a UPLC system. A 30 µ L reaction containing 25 mM HEPES buffer with 125 mM NaCl, 20 µ M UDP-Galf, 10 mM sodium dithionite, 10 nM UGM (concentration based on FAD), 2% DMSO, and inhibitor (0–1 mM) were incubated at 25 °C for 3 min. Protein and inhibitor were pre-incubated for 5 min at 25 °C in reaction buffer (25 mM HEPES containing 125 mM NaCl) and the reaction was started with the addition of 3 µL of 200 µM UDP-Galf. The reaction was quenched with the addition of 70 µL acetonitrile. After removing the protein by centrifugation, 5 µ L of sample was injected into an Amide column (Acquity UPLC BEH Amide, 1.7 µ m, 2.1 mm × 100 mm) at 45 °C. The UPLC column was pre-equilibrated with 75% acetonitrile and 25% 27 mM aqueous HPLC-grade potassium phosphate (pH 4.5). Samples were run at a flow rate of 0.5 mL/min for 5 min. IC was also determined by following NADPH oxidation at 340 nm. The reaction mix consisted of 250 µ M NADPH, 25 mM HEPES with 125 mM NaCl, 2.5 µ M UGM, 2% DMSO, and inhibitor (0–1 mM). Data was analyzed using KaleidaGraph software. The type of inhibition was assessed by spectropho- tometrically (340 nm) recording the oxidation of various concentrations of NADPH (0–1 mM) in 25 mM HEPES containing 125 mM NaCl with 2.5 µ M UGM (based on FAD) at different concentrations of inhibitor with 2% DMSO in the absence of UDP-Galf. Global t fi ting was performed with Graphpad Prims 6 software (La Jolla, CA). ITC measurement. Binding of inhibitors to UGM was measured with an Auto-ITC 200 ITC instrument. UGM was dialyzed in 50 mM potassium phosphate bue ff r, pH 7.0, for 2 h at 4 °C. In all cases, ligands were dis- solved in dialysis buffer and protein and ligand were filtered with a 0.2 µ M membrane prior to loading. UGM concentration was 46 µ M in all titrations and the concentrations of NADP and UDP in the syringe were 16.8 mM and 400 µ M, respectively. Inhibitor concentration in the syringe was 2 mM (2% DMSO), except for chrysin where the concentration was 600 µ M (4% DMSO). Titration was performed in 16 injections of 2.5 µ L with spacing of 180S at 25 °C with continuous stirring at 750 rpm. Thermodynamic parameters were determined from ITC results using Microcal Origin version 7.0 (OriginLab) with the “ITC custom” add-on installed. Effect of (2S )-hesperetin and (2S)-naringenin on A. fumigatus growth. Spores of A. fumigatus from ATCC were germinated in potato dextrose agar (PDA). Spores were harvested using a sterile plastic scraper from 3 day old cultures grown at 37 °C and suspended in phosphate saline buffer containing 0.1% Tween-20. Inhibitor effect on cell growth was tested in 12-well plates (Falcon, 353043) containing 700 µ L agar at a final DMSO concentration of 1% and spot inoculated with 1 × 10 spores. For the toxicity studies, complete medium PDA containing 100–1000 µ M of inhibitor was spot inoculated with 1 × 10 spores and incubated at 37 °C. A control was inoculated into PDA with DMSO. Inhibitor or DMSO was mixed with the PDA agar before solidi- fying. For congo red susceptibly assays, inhibitors at 100 µ M concentration were added to aspergillus minimum media (AMM) containing congo red (1.0 and 0.5 mg/mL) before the agar jellified. The working concentrations 39 3 of congo red were determined by a serial dilution method in a 12-well plate inoculated with 1 × 10 spores and grown at 37 °C for 48 h. As the negative control, inoculated agar containing either congo red or 100 µM inhibitor were employed. For the thermotolerance studies, PDA medium containing 1000 µM of inhibitor was spot inocu- 3 5 lated with 1 × 10 and 1 × 10 spores and incubated at 50 °C for 48 h. As control, agar with DMSO was employed. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 8 www.nature.com/scientificreports/ References 1. Latgé, J.-P. Aspergillus fumigatus and Aspergillosis. Clin. Microbiol. Rev. 12, 310–350 (1999). 2. Reece, E. et al. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic b fi rosis patients: an Irish registry analysis. BMC Pulm. Med. 17, 70; doi:10.1186/s12890-017-0416-4 (2017). 3. Low, C.-Y. & Rotstein, C. Emerging fungal infections in immunocompromised patients. F1000 Med. Rep. 3, 14; doi:10.3410/M3-14 (2011). 4. Taccone, F. S. et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Cri. Care 19, 7; doi:10.1186/s13054-014-0722-7 (2015). 5. Latgé, J.-P. Tasting the fungal cell wall. Cell. Microbiol. 12, 863–872 (2010). 6. Latgé, J.-P. & Beauvais, A. Functional duality of the cell wall. Curr. Opin. Microbiol. 20, 111–117 (2014). 7. Stynen, D. et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect. Immun. 60, 2237–2245 (1992). 8. Barreto-Bergter, E. & Figueiredo, R. T. Fungal glycans and the innate immune recognition. Front. Cell. Infect. Microbiol. 4, 145; doi:10.3389/fcimb.2014.00145 (2014). 9. Latgé, J.-P. Galactofuranose containing molecules in Aspergillus fumigatus. Med. Mycol. 47, S104–S109; doi:10.1080/13693780802258832 (2009). 10. Latgé, J. P. et al. Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect. Immun. 62, 5424–5433 (1994). 11. Leitão, E. A. et al. β-Galactofuranose-containing O-linked oligosaccharides present in the cell wall peptidogalactomannan of Aspergillus fumigatus contain immunodominant epitopes. Glycobiology 13, 681–692 (2003). 12. Schmalhorst, P. S. et al. Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus. Eukaryotic Cell 7, 1268–1277 (2008). 13. Pan, F., Jackson, M., Ma, Y. & McNeil, M. Cell wall core galactofuran synthesis is essential for growth of Mycobacteria. J. Bacteriol. 183, 3991–3998 (2001). 14. Kumar, S. et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS One 2, e1189; doi:10.1371/ journal.pone.0001189 (2007). 15. Latha, A. A. & Narayanan, R. B. UDP-galactopyranose mutase as a possible drug target for the human filarial parasite, Brugia malayi : an in silico evaluation. Int. J. Med. Eng. Inf. 5, 372–382 (2013). 16. Novelli, J. F. et al. Characterization of the Caenorhabditis elegans UDP-galactopyranose mutase homolog glf-1 reveals an essential role for galactofuranose metabolism in nematode surface coat synthesis. Dev. Biol. 335, 340–355 (2009). 17. Kleczka, B. et al. Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J. Biol. Chem. 282, 10498–10505 (2007). 18. Oppenheimer, M., Poulin, M. B., Lowary, T. L., Helm, R. F. & Sobrado, P. Characterization of recombinant UDP-galactopyranose mutase from Aspergillus fumigatus. Arch. Biochem. Biophys. 502, 31–38 (2010). 19. Mehra-Chaudhary, R., Dai, Y., Sobrado, P. & Tanner, J. J. In crystallo capture of a covalent intermediate in the UDP-galactopyranose mutase reaction. Biochemistry 55, 833–836 (2016). 20. Oppenheimer, M., Valenciano, A. L., Kizjakina, K., Qi, J. & Sobrado, P. Chemical mechanism of UDP-galactopyranose mutase from Trypanosoma cruzi: a potential drug target against Chagas’ disease. PLoS One 7, e32918; doi:10.1371/journal.pone.0032918 (2012). 21. Dhatwalia, R. et al. Identification of the NAD(P)H binding site of eukaryotic UDP-galactopyranose mutase. J. Am. Chem. Soc. 134, 18132–18138 (2012). 22. Qi, J., Kizjakina, K., Robinson, R., Tolani, K. & Sobrado, P. A fluorescence polarization binding assay to identify inhibitors of flavin- dependent monooxygenases. Anal. Biochem. 425, 80–87 (2012). 23. Feng, B. Y. & Shoichet, B. K. A Detergent-based assay for the detection of promiscuous Inhibitors. Nat. Protoc. 1, 550–553 (2006). 24. Thorne, N., Auld, D. S. & Inglese, J. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315–324 (2010). 25. Sucharitakul, J., Prongjit, M., Haltrich, D. & Chaiyen, P. Detection of a C4a-hydroperoxyflavin intermediate in the reaction of a flavoprotein oxidase. Biochemistry 47, 8485–8490 (2008). 26. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49, 7274–7277 (2006). 27. Valiante, V., Macheleidt, J., Föge, M. & Brakhage, A. A. The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Front. Microbiol. 6, 325; doi:10.3389/fmicb.2015.00325 (2015). 28. Ghannoum, M. A. & Rice, L. B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12, 501–517 (1999). 29. Vincent, S. et al. Natural and synthetic flavonoids as potent Mycobacterium tuberculosis UGM inhibitors. Chem. - Eur. J. 23, 10423–10429 (2017). 30. Peltier , P . et al. Synthetic UDP-furanoses as potent inhibitors of mycobacterial galactan biogenesis. Chem. Biol. 17, 1356–1366 (2010). 31. Frédéric, C. J. M. et al. Synthesis of unprecedented sulfonylated phosphono-exo-glycals designed as inhibitors of the three Mycobacterial galactofuranose processing enzymes. Chem. – Eur. J. 22, 15913–15920 (2016). 32. Choi, E. M. & Lee, Y. S. Effects of hesperetin on the production of inflammatory mediators in IL-1beta treated human synovial cells. Cell. Immunol. 264, 1–3 (2010). 33. Bai, X. et al. The protective effect of the natural compound hesperetin against fulminant hepatitis in vivo and in vitro. Br. J. Pharmacol. 174, 41–56 (2017). 34. Zhu, C., Dong, Y., Liu, H., Ren, H. & Cui, Z. Hesperetin protects against H O -triggered oxidative damage via upregulation of the 2 2 Keap1-Nrf2/HO-1 signal pathway in ARPE-19 cells. Biomed. Pharmacother. 88, 124–133 (2017). 35. Liu, D. et al. Inhibitory effect of hesperetin and naringenin on human UDP-glucuronosyltransferase enzymes: implications for herb–drug interactions. Biol. Pharm. Bull. 39, 2052–2059 (2016). 36. Lopes, L. A. A., dos S Rodrigues, J. B., Magnani, M., de Souza, E. L. & de Siqueira-Júnior, J. P. Inhibitory effects of flavonoids on biofilm formation by Staphylococcus aureus that overexpresses efflux protein genes. Microb. Pathog. 107, 193–197 (2017). 37. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13, 869–874 (2008). 38. Chodera, J. D. & Mobley, D. L. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu. Rev. Biophys. 42, 121–142 (2013). 39. Ram, A. F. J. & Klis, F. M. Identification of fungal cell wall mutants using susceptibility assays based on calcouo fl r white and congo red. Nat. Protoc. 1, 2253–2256 (2006). 40. Martín del Campo, J. S. et al. Inhibition of the flavin-dependent monooxygenase siderophore A (SidA) blocks siderophore biosynthesis and Aspergillus fumigatus growth. ACS Chem. Biol. 11, 3035–3042 (2016). 41. Forneris, F., Orru, R., Bonivento, D., Chiarelli, L. R. & Mattevi, A. ThermoFAD, a Thermouo fl r -adapted flavin ad hoc detection system for protein folding and ligand binding. FEBS J. 276, 2833–2840 (2009). 42. Schrettl, M. et al. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J. Exp. Med. 200, 1213–1219 (2004). SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 9 www.nature.com/scientificreports/ Acknowledgements This work was supported by a National Institutes of Health Grant GM094469 and funds from the Fralin Life Science Institute. We are grateful to Dr. Karina Kizjakina for synthesizing and purifying the UDP-Galf. Author Contributions J.S.M.C. wrote the main manuscript, performed H.T.S., inhibition, cell assays, and data analysis. M.E. performed I.T.C. measurements and prepared I.T.C. figures. N.V. optimized and performed the H.T.S. assay. P.S. supervised the project and wrote the manuscript. All authors reviewed the manuscript. Additional Information Supplementary information accompanies this paper at doi:10.1038/s41598-017-11022-5 Competing Interests: The authors declare that they have no competing interests. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre- ative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not per- mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2017 SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 10 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Scientific Reports Springer Journals

Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors

Loading next page...
1
 
/lp/springer_journal/identification-of-aspergillus-fumigatus-udp-galactopyranose-mutase-0V2nuPg3zP

References (41)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Science, Humanities and Social Sciences, multidisciplinary; Science, Humanities and Social Sciences, multidisciplinary; Science, multidisciplinary
eISSN
2045-2322
DOI
10.1038/s41598-017-11022-5
Publisher site
See Article on Publisher Site

Abstract

www.nature.com/scientificreports Correction: Author Correction OPEN Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors Received: 30 May 2017 1 1 2 1,2 Julia S. Martin del Campo , Meital Eckshtain-Levi , Nancy J. Vogelaar & Pablo Sobrado Accepted: 17 August 2017 Aspergillus fumigatus is an opportunistic human pathogen responsible for deadly, invasive infections Published: xx xx xxxx in immunocompromised patients. The A. fumigatus cell wall is a complex network of polysaccharides among them galactofuran, which is absent in humans. UDP-galactopyranose mutase (UGM) catalyzes the conversion of UDP-galactofuranose (UDP-Galf) to UDP-galactopyranose (UDP-Galp) and is an important virulence factor. UGM is a flavin-dependent enzyme that requires the reduced flavin for activity; flavin reduction is achieved by reaction with NADPH. The aim of this work was to discover inhibitors of UGM by targeting the NADPH binding site using an ADP-TAMRA probe in a high- throughput screening assay. The flavonoids (2S)-hesperetin and (2S)-naringenin were validated as competitive inhibitors of UGM against NADPH with K values of 6 µM and 74 µM, respectively. To gain insight into the active chemical substituents involved in the inhibition of UGM, several derivatives of these inhibitors were studied. The results show that the hydroxyl groups of (2S)-hesperetin are important for inhibition, in particular the phenyl-chroman moiety. Congo red susceptibility assay and growth temperature effects showed that these compounds affected cell wall biosynthesis in A. fumigatus. This work is the first report of inhibition studies on UGM from eukaryotic human pathogens. Aspergillus fumigatus is a common opportunistic human pathogen that causes infections such as allergic bron- 1,2 chopulmonary aspergillosis and invasive pulmonary aspergillosis, among others . Patients with acute leukemia, hematopoietic stem cell transplant recipients, and solid-organ transplant recipients are the three most common groups of patients at risk of invasive A. fumigatus infections . Although drugs are available for treating A. fumiga- tus infections, the mortality rate among immunocompromised persons is >50% . The fungal cell wall is essential to maintaining cell integrity and plays an important role in host-pathogen interactions. Several cell wall compo- nents are fungal specific and absent in mammals . The cell wall of A. fumigatus consists of a three-dimensional arrangement of polysaccharides. The central core is composed of branched β−1,3-glucan cross-linked to chitin. The external core of the cell wall is composed of glucose chains of β -1,3–1,4 glucan and galactomannan, which makes the structure unique compared to other fungi . Galactomannans are the major antigens produced during infection by A. fumigatus and possibly act as components of extracellular adhesive structures during host tissue invasion . Secreted galactomannan is composed of a branched core containing α(1 → 2)- and α(1 → 6)-linked mannose, with β(1 → 5)-galactofuranose and/or β(1 → 4)-galactopyranose moieties linked linearly in side chains 7,10,11 terminated by galactofuranose non-reducing end units (Fig. 1a). Galactofuranose (Galf) is a five-member cyclic hexose found in several pathogens but is absent in humans. The synthesis of Galf starts in the cytosol where UDP-galactopyranose (UDP-Galp) is transformed to UDP-Galf by UDP-galactofuranose mutase (UGM, Fig. 1b). UGM is a key enzyme in the biosynthesis of galactofuranose containing glyco-conjugates. Deletion of A. fumigatus UGM prevents Galf production and results in a strain with reduced cell wall thickness and attenuated virulence in mice . In addition, UGM has been shown to be essential for the pathogenesis of Mycobacterium 13 14,15 tuberculosis and for larval hatching and long-term survival of the nematodes Brugia malayi and Caenorhabditis elegant . In the protozoan pathogen Leishmania major, UGM has also been identified as a vir - ulence factor . UGM is a flavoenzyme that catalyzes a non-redox reaction; however, the flavin is required to be in the reduced form for catalysis . The catalytic cycle of UGM starts with NADPH binding, then reduction of the FAD occurs and, finally, release of NADP (Fig. 1b,i–iii). UDP-Galp binds to the reduced UGM (Fig. 1b,iv) and the chemical steps are initiated by nucleophilic attack of the FAD N5 atom to the Galp C1 atom, generating 1 2 Department of Biochemistry, Virginia Tech, Blacksburg, VA, 24061, USA. Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA, 24061, USA. Correspondence and requests for materials should be addressed to P.S. (email: psobrado@vt.edu) SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 1 www.nature.com/scientificreports/ Figure 1. (a) Depiction of secreted galactomannan showing the (1 → 5)-linked Galf chains bound to mannose units (M). (b) Chemical mechanism for UGM. The activation of UGM by NADPH is depicted in i and ii. The reduced activated enzyme (iii), binds to UDP-Galp and a covalent flavin–galactose adduct is formed via the direct attack of the FAD-N5 atom to the Galp-C1 atom. This step leads to cleavage of the anomeric bond (iv-v). Tautomerization of the flavin permits the transfer of the FAD-N5-proton (shown in red) to the C4FAD = O (vi). This proton is next transferred to the Galp-C5-O, facilitating the opening of the sugar ring and formation of the flavin iminium ion (vi-vii). The FAD-C4 = O is predicted to accept the proton from the Galp-C4-OH (shown in blue) during ring contraction (viii). The final step is the direct attack of UDP to the FAD–galactofuranose adduct (ix-x). a flavin-Galp intermediate (Fig. 1b,iv–v). Formation of a flavin-sugar iminium ion leads to opening of the sugar ring (Fig. 1b,vi–vii). After recyclization, attack by UDP releases the sugar of the flavin and forms the product, UDP-Galf (Fig. 1b,viii–x) . UGMs can react with molecular oxygen leading to the oxidation of the flavin, which is the inactive form of the enzyme (Fig. 1b,i). FAD oxidation occurs very slowly aer ft following several hundred mutase reactions . Crystallographic data showed that the ADP group of NAD(P)H and the UDP group of the substrate have independent binding pockets, while the nicotinamide riboside binding site overlaps with the binding of the Galp 19,21 moiety in order to access the flavin N5 atom . The unique arrangement of the NAD(P)H binding domain of UGM represents an attractive target for the design of inhibitors of the oxidized (inactive) enzyme that bind in the pocket, which is unique to the ADP component of NADPH. In this work, a 2320 compound library was screened against oxidized A. fumigatus UGM using a TAMRA labeled ADP (ADP-TAMRA) . The flavonoids (2S )-hesperetin and (2S)-naringenin were identified as compet- itive inhibitors against NADPH. Binding of inhibitors caused an increase in the melting temperature of UGM (~2.7 °C). Inhibition studies of (2S)-hesperetin derivatives allowed us to identify the hydroxyl group of the phenyl-chroman moiety as essential for binding and inhibition. In cultures of A. fumigatus, (2S)-hesperetin and (2S)-naringenin increased thermosensitivity and susceptibility to the cell wall stressing agent congo red. This work represents the first efforts in inhibitor discovery against eukaryotic UGM. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 2 www.nature.com/scientificreports/ Figure 2. (a) HTS against UGM using ADP-TAMRA (30 nM). (b) Funnel diagram illustrating the processes of inhibitor identification and validation. Results High-throughput screening assay and hit validation. Previously, our group developed an ADP- TAMRA probe to identify inhibitors of flavin-dependent monooxygenases that use NADPH as a substrate . To determine the utility of ADP-TAMRA to search for inhibitors of recombinant A. fumigatus UGM (UGM, from here on), ADP-TAMRA binding was tested as a function of UGM concentration. The observed increase in the anisotropy as a function of UGM concentration permitted the calculation of a K value of 6.7 µ M (Fig. S1a). Competitive binding of ADP or NADP against ADP-TAMRA (Fig. S1b) was confirmed from the K value of the UGM-chromophore complex (anisotropy value of ~0.18) upon addition of increasing concentrations of either ligand. Thus, the change in anisotropy, upon release of ADP-TAMRA from the active site of UGM was used as the signal for a high-throughput screening (HTS) assay to identify small compounds that bound to UGM. Using this HTS assay, the Spectrum Collection library (2320 compounds) was screened against UGM at 20 µ M concentra- tion (2% DMSO) as described in the methods section. The Spectrum library was selected because of its diverse composition of bioactive compounds (60%), natural compounds of unknown biological properties (25%), and compounds representative of known drug-enzyme inhibitors, among others. It is known that aggregate-based inhibition is time dependent . In order to remove aggregators from screen- ing, we measured the anisotropy after incubation at 30 min and 120 min. The die ff rence between the two-time point readings was used to assess aggregation. Compounds with absolute difference in anisotropy between read- ings that was greater than 12% (corresponding to 3 standard deviations of the negative control) were considered aggregators and not studied further, leaving 2130 compounds (Fig. 2a). The average Z′ factor was calculated to be 0.82 ± 0.04, which indicates a wide separation between positive and negative controls. Hits were defined as compounds that had an anisotropy ≤ 50% at 30 min incubation (Fig. 2b). From the 26 identified hits, compounds that oxidized NADPH were removed. Only 13 compounds were commercially available and they were classified as flavonoids and non-flavonoids (Table S1). Inhibition of product formation followed by UPLC at 20 and 200 µ M compound concentration in 2% DMSO allowed for the identification of five compounds that exhibited a concentration dependent potency: (2S)-hesperetin, (2S)-naringenin, and chrysin from the flavo- noid family, and diclazuril and febuxostat from the non-flavonoid family. The melting temperature of UGM (meas- ured with the ThermoFAD method) with 20, 100, and 1000 µ M of compound (2% DMSO and 1 mg/mL UGM) indicated that diclazuril and febuxostat are UGM denaturants, as these compounds reduced the T compared to the reference (UGM alone in 2% DMSO) and were not further studied. Chrysin showed no effect on T and (2S)-hesperetin and (2S)-naringenin increased the T by ~2.7 °C. The positive shift in T caused by (2S)-hesperetin m m and (2S)-naringenin (Fig. S2) is comparable to the effect of 10 mM UDP, which causes a shift of 3 °C. Determination of IC , K values, and the mechanism of inhibition of UGM inhibitors. IC val- 50 D 50 ues were determined with the UPLC method using sodium dithionite as the reducing agent (Fig. 3a,b). Chrysin showed the highest potency followed by (2S)-hesperetin and (2S)-naringenin (Table 1). However, the IC curve of chrysin saturated below full enzyme inhibition (~35% activity, ~30 µ M chrysin), and precipitated above 100 µ M (with 2% DMSO). These behaviors agree with the reported mechanism that involves the formation of a colloidal aggregate by the compound, which precipitates as the concentration rises . As expected, chrysin did not inhibit NADPH oxidation, nor was binding detected with ITC. The IC for (2S)-hesperetin and (2S)-naringenin was also determined by following NADPH oxidation by UGM in the absence of UDP-Galf (Fig. 3c,d). It was found that (2S)-hesperetin and (2S)-naringenin inhibited NADPH oxidation. The type of inhibition by (2S)-hesperetin and (2S)-naringenin was assessed with the NADPH oxidation assay at different concentrations of inhibitor. (2S)-Hesperetin and (2S)-naringenin were competitive against NADPH. The K values for (2S)-hesperetin and (2S)-naringenin were 6 ± 1 µ M and 74 ± 24 µ M, respectively. The K for all ligands was determined by ITC meas- urement. The K values for (2S)-hesperetin and (2S)-naringenin were higher than that for NADP and lower than that for UDP (Fig. 4 and Table 2). Interestingly, the binding of NADP , (2S)-naringenin, and (2S)-hesperetin was SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 3 www.nature.com/scientificreports/ Figure 3. Characterization of UGM inhibitors. IC curves obtained with UPLC activity assay for (a) (2S)- hesperetin and (b) (2S)-naringenin. IC curves for (c) (2S)-hesperetin and (d) (2S)-naringenin obtained by following NADPH oxidation. Double reciprocal plots for the NADPH oxidation by UGM in the presence of (e) (2S)-hesperetin or (f ) (2S)-naringenin. IC (µM) Name Chemical Structure UPLC NADPH oxidation Type of Inhibition K (µM) (2S)-hesperetin 40 ± 3 32 ± 7 Competitive (NADPH) 6 ± 1 (2S)-naringenin 161 ± 11 233 ± 28 Competitive (NADPH) 74 ± 24 Chrysin 24 ± 4 >1 mM — — Table 1. Characterization of UGM inhibitors identified by HTS of the Spectrum library using ADP-TAMRA. IC was determined with 20 µM UDP-Galf (UPLC) and 10 mM sodium dithionite and for the NADPH oxidation was determined with 250 µM NADPH and no substrate. exothermic; the enthalpy driven binding of NADP , (2S)-naringenin, and (2S)-hesperetin could indicate the formation of hydrogen bonds along with conformation changes. While the entropy driven binding of UDP could be related to hydrophobic interaction and water release. Inhibition studies of (2S)-hesperetin and (2S)-naringenin derivatives. To characterize the structural components important for inhibition, commercially available derivatives of (2S)-hesperetin and (2S)-naringenin were studied. The selected compounds included modification in the phenyl moiety and/or in the dihydroxrychroman SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 4 www.nature.com/scientificreports/ Figure 4. Representative ITC results and fitting curves for substrates and inhibitors binding to UGM. (a) UDP and (b) NADP are shown for reference. (c) (2S)-hesperetin and (d) (2S)-naringenin. −1 −1 −1 Compound ∆G(kcal•mol ) ∆H(kcal•mol ) T•∆S(kcal•mol ) K (µM) UDP −7.1 ± 0.1 3.3 ± 0.1 10.5 ± 0.3 5.4 ± 0.8 NADP −4.6 ± 0.3 −13.0 ± 0.3 −8.4 ± 0.7 413 ± 24 (2S)-hesperetin −6.1 ± 0.4 −4.1 ± 0.4 2.1 ± 0.2 31 ± 6 (2S)-naringenin −5.7 ± 1.0 −4.8 ± 1.0 0.9 ± 0.3 65 ± 13 Table 2. er Th modynamic parameters for the ligands UDP, NADP and inhibitors binding to A. fumigatus UGM. moiety of (2S)-hesperetin as well as different hydroxychroman structures (Fig.  5a). (2S)-isosakuranetin was the only compound that inhibited the activity of UGM with an IC of 113 ± 9 µ M (UPLC assay, Fig. S3) and was not competitive with NADPH. The IC for (2S)-isosakuranetin is comparable to the IC of (2S)-naringenin. 50 50 (2S)-isosakuranetin increased the T of UGM by 1.3 ± 0.2 °C. This change in T is half the increase caused by m m (2S)-hesperetin and (2S)-naringenin (Fig. S2). No binding of (2S)-isosakuranetin to UGM was detected using ITC measurements. The structural difference between (2S )-hesperetin, (2S)-naringenin, and (2S)-isosakuranetin lies in the substituents of the phenyl group. In (2S)-hesperetin, the phenyl ring contains the 3-hydroxy-4-methoxy groups, while (2S)-naringenin and (2S)-isosakuranetin lack the 4-methoxy or the 3-hydroxy substituent, respectively. Modification in the 5,7-dihydroxrychroman-4-one moiety of (2S )-naringenin, specifically removing the 5-hydroxyl group of (2S)-naringenin, results in the compound liquiritigenin with no inhibitory effect against UGM. The R enan- tioniomer of naringenin and the dihydroxychroman derivatives showed no inhibition of UGM. Activity of UGM inhibitors in A. fumigatus cultures. We observed no A. fumigatus toxicity with (2S)-hesperetin and (2S)-naringenin at 1000 µ M in PDA medium at 37 °C (Fig. S4). We performed combined sus- ceptibility assays to congo red (0.5 and 1 mg/mL) with 100 µM (2S)-hesperetin and (2S)-naringenin. Aer 48 ft h of incubation at 37 °C we observed a growth decrease of ~50% and ~30% with (2S)-hesperetin and (2S)-naringenin respectively (Fig. 5b). When A. fumigatus was grown for 48 h at 50 °C in PDA with 1000 µ M (2S)-hesperetin or (2S)-naringenin, we observed a delay in colony development of ~50% and ~30% respectively when compared with the reference (Fig. S5). Discussion e ce Th ll wall of A. fumigatus is a complex and dynamic structure able to reprogram its composition to overcome genetic deficiencies and environmental stress . Current drugs against invasive and systemic A. fumigatus infec- tions include polyenes (e.g., amphotericin B), azoles (e.g., voriconazole), and echinocandins (e.g., caspofungin). Polyenes can bind to sterols and form pores in the cell membrane leading to increased membrane permeabil- ity. Azoles can block ergosterol biosynthesis causing an accumulation of lanosterol that reach toxicity levels. 27,28 Echinocandins are the only antifungals that target the cell wall by inhibiting β-1,3-glucan synthase . During infection, cell walls containing galactofuranose polysaccharides, specifically galactomannan, play important roles in host immune recognition . Secreted galactomannans in association with galactosamino- galactans are the major components of the biofilm mycelia found in aspergilomas and pulmonary lesions . UGM is a key enzyme in the biosynthesis of galactofuran-containing molecules and is a virulence factor in A. fumigatus . There are several research reports of inhibitors targeting the UDP-Gal p binding site of prokary- otic UGM. Recently, natural and synthetic flavonoids were reported as M. tuberculosis UGM inhibitors with a non-competitive mechanism of action . Different approaches to developing UGM inhibitors have been reported. These includes a cell-free enzymatic synthesis of UDP-Galf derivatives modified at C-5 and C-6, which pre- vent mycobacterial galactan polymerization . To date, there are no reports of inhibitors that target the unique NADPH binding site of UGM. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 5 www.nature.com/scientificreports/ Figure 5. (a) Structures of the (2S)-hesperetin and (2S)-naringenin derivatives studied in this work. (b) Susceptibility of A. fumigatus to congo red (0.5 mg/mL) and 100 µM (2S)-hesperetin and (2S)-naringenin. (c) Graphical depiction of the proposed attenuation strategy against A. fumigatus virulence. Inhibition of UGM traps it in its oxidized, or inactive, state and leads to the abolishment of UDP-Galf production and cell wall weakening. In this work, we reported that (2S)-hesperetin competitively inhibits UGM in its oxidized state by binding to the NADPH site and that (2S)-hesperetin is able to inhibit the conversion of UDP-Galf to UDP-Galp with an IC of 40 µ M. The potency of (2 S)-hesperetin is higher than the most recent report targeting the UDP-Galf binding site of UGM from M. tuberculosis where, exo-glycans bearing both a sulfone and a phosphonate irrevers- ibly inhibited UGM with an IC of 77 µ M . These two compounds, (2 S)-hesperetin and (2S)-naringenin, are flavonones found in citrus (orange and grapefruit). (2S )-Hesperetin is known to be an anti-inflammatory and 32 33 immunomodulatory agent . (2S)-hesperetin has shown cytoprotective activity in models of acute liver toxicity and has a protective effect against H O -induced oxidative damage in ARPE-19 cells . Nevertheless, it has been 2 2 reported that (2S)-hesperetin and (2S)-naringenin have an inhibitory effect on UDP-glucuronosyltransferases . Antimicrobial activities of (2S)-hesperetin include biofilm formation inhibition > 70% against S. aureus strains, where the formation of biofilm by S. aureus is associated with the synthesis of an extracellular β -1,6-linked N-acetyl (succinyl) glucosamine polymer . (2S)-Hesperetin and (2S)-naringenin were shown to be competitive inhibitors against NADPH, suggesting that these compounds bind to the active site of UGM. Thus, these compounds can prevent activation of UGM by blocking NADPH binding. Furthermore, these compounds effectively block the mutase activity of UGM as inhibition of chemically reduced UGM was also observed. It is possible that binding of flavonoids prevents 19,21 proper closing of the active site flaps and, thus, UDP binding . The thermodynamic behavior of the interaction SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 6 www.nature.com/scientificreports/ between UGM and (2S)-hesperetin and (2S)-naringenin resembles the binding of NADP , which is exothermic and enthalpy-driven. In contrast, the binding of UDP is endothermic and entropy-driven. Binding enthalpies between (2S)-hesperetin and (2S)-naringenin are not significantly different. Even so, the IC and K values of 50 i (2S)-hesperetin are about 10 times lower than for (2S)-naringenin. The discrepancy between binding enthalpies and inhibition constants could be a consequence of enthalpy gain compensated by entropy loss resulting from 37,38 strong hydrogen bonds between UGM and (2S)-hesperetin and, most likely, by the methoxy and hydroxy sub- stituents of the phenyl ring of (2S)-hesperetin. (2S)-Hesperetin and (2S)-naringenin have a stabilizing effect on UGM, increasing the melting temperature. e Th increased stability is attributed to a tighter conformation resulting from the binding of a small molecule. It has been reported that cell wall mutants are generally more sensitive to the anionic dye congo red, which interferes with the construction and stress response of the cell wall. The susceptibility to congo red is a response related to an increase in chitin deposition in the cell wall product of disturbed synthesis of β-1,3-glucan or β-1,6-glucan, mannosylation of mannoproteins, and glycosylphosphatidylinositol biosynthesis, among others . We observed an increased susceptibility to congo red in the presence of (2S)-hesperetin and (2S)-naringenin that could be related to changes in the galactomannan biosynthesis induced by partial UGM inhibition. Future crystallography studies of UGM with (2S)-hesperetin and (2S)-naringenin will allow design and optimization of more potent inhibitors of eukarytoic UGMs. Materials and Methods Materials. Buffers, antibiotics, and bacterial growth media were obtained from Fisher Scientific (Pittsburg, PA) and Sigma-Aldrich (St. Louis, MO). Turbo BL21 (DE3) chemically competent cells were obtained from Genlantis (San Diego, CA). For protein purification, an AKTA prime system (GE Healthcare) was used along with IMAC columns (GE Healthcare). Acquity ultraperformance liquid chromatography (UPLC) and Amide (1.7 µm, 2.1 mm × 100 mm) analytical columns were obtained from Waters (Milford, MA). NADPH was obtained from EMD Biosciences (Billerica, MA). UDP-Galf was synthesized as described previously . The Spectrum Collection library was purchased from Microsource (Gaylordsville, CT). For the FP assay, non-binding, surface black 384- well plates were purchased from Greiner Bio-One (Monroe, NC) and samples were analyzed on a Spectramax M5 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). Differential scanning fluorimetry was performed in an RT-PCR (Applied Biosystems 7300) using 96-well RT-PCR plates (Microamp 4306737) with optical adhesive films (MicroAmp 431197971). ITC measurements were performed in an Auto-ITC 200 from Malvern Instruments (Malvern, United Kingdom) and analyzed using the Microcal Origin version 7.0 from OriginLab (Northampton, MA). (2S)-Hesperetin was purchased from TCI America (Portland, OR) and (2S)- naringenin and (2S)-isosakuranetin from Fisher Scientic fi (Asheville, NC). (2 R)-naringenin was purchased from Vitas-M Laboratory (Champaign, IL). 5,7-dihydroxy-2,2-dimethylchroman-4-one was purchased from Hit2Lead (San Diego, CA). 7-hydroxychroman-4-one, 4-chroman, and liquiritigenin were purchased from ArkPharm (Arlington Heights, IL). Dehydrated potato dextrose agar was from BD Difco (Franklin Lakes, NJ) and Aspergillus fumigatus strain 46645 was purchased from the American Type Culture Collection (ATCC, Manassas, VA). Expression and purification of A. fumigatus UGM. UGM was expressed in the vector pVP55A as reported previously . Briefly, 6-L of terrific broth auto induction media containing 100 μg/ml ampicillin were inoc- ulated with 8 mL of overnight culture of BL21 Turbo cells transformed with the vector pPV55A and inoculated at 37 °C until an O.D. of 3 was reached. Then, the temperature was dropped to 18 °C and cultures were incubated for 18 additional hours. Cells were harvested by centrifugation at 5000 g for 20 min at 4 °C. The final wet-cell pellet (75 g) was stored at −80 °C. For protein purification, the cell paste was suspended in 250 mL of buffer A (25 mM HEPES, 300 mM NaCl, 25 mM imidazole, pH 7.5) and incubated with 25 mg/mL of lysozyme, DNAse I, and RNAse for 45 min at 4 °C with constant stirring. The resulting solution was sonicated in an ice bath for 15 min at 70% amplitude at cycles of 5S ON and 10S OFF. The lysate was centrifuged at 45,000 g for 45 min and the supernatant was collected and loaded onto three in-tandem 5 mL HisTrap columns previously equilibrated with buffer A. Aer lo ft ading was completed, the columns were washed with buffer A until the absorbance at 280 nm returned to baseline levels. UGM was eluted with Buffer B (25 mM HEPES, 300 mM NaCl, 300 mM imidazole, pH 7.5). To remove the 8× His-tag, the protein was dialyzed in the presence of 8× His-tobacco etch virus (8× His-Tev) protease (1:20 ratio) at 4 °C with slow stirring in buffer C (25 mM HEPES, 300 mM NaCl, pH 7.5). The dialyzed sample was loaded back onto the IMAC, previously equilibrated with buffer C, and the flow-through containing UGM was collected. The buffer of the purie fi d UGM was exchanged to 25 mM HEPES with 100 mM NaCl, a fl sh frozen, and stored at −80 °C until use. Binding of ADP-TAMRA to UGM and competition with NADP and UDP. Our group previously developed a binding assay to identify inhibitors of flavoenzymes that use NADP(H) as substrate. Since UGM also used NADPH for reduction, we determined whether this compound bound to UGM. This was done by taking the ADP-TAMRA chromophore to a final concentration of 30 nM in 25 mM HEPES buffer, pH 7.5, mixed with various concentrations of UGM (0–300 µ M, based on Bradford). To determine if the chromophore was binding to the active site of UGM, the competitive binding of UDP (0–1 mM) and NADP (0–10 mM) was calculated by measuring the decrease in anisotropy of the UGM (6.7 µ M) - ADP-TAMRA (30 nM) complex. At each concentra- tion of ligand, the solution was incubated for 10 min at room temperature. e s Th ample was excited at 544 nm and the emission recorded at 584 nm using a wavelength cutoff of 570 nm. High-throughput screening. High-throughput screening of the Spectrum Collection library using the FP assay with the ADP-TAMRA probe was performed at the Virginia Tech Center for Drug Discovery Screening Laboratory. 384 well plates (Greiner 784900) were used and the reaction volume was 15 µL using 25 mM HEPES SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 7 www.nature.com/scientificreports/ buffer (pH 7.0). For the screening, 30 nM of ADP-TAMRA with 6.7 µ M UGM (based on the Bradford assay) and 20 µ M of library compound were used, with a final DMSO concentration of 2%. Fluorescence polarization measurements were performed with excitation at 544 nm and emission at 584 nm, using a wavelength cutoff of 570 nm. Anisotropy measurements were performed aer 30 a ft nd 120 minutes of incubation at 25 °C. Anisotropy values were normalized to the values obtained in the negative control sample: UGM, ADP-TAMRA, and DMSO (high anisotropy values). The positive control consisted of ADP-TAMRA and DMSO (low anisotropy values). The Z prime (Z′) value was determined using equation (1) where, σ and μ represent the standard deviation and N,P N,P the mean value the of the negative and positive controls respectively. 3(σσ + ) NP Z′= 1 − μμ − (1) NP Hydrogen peroxide quantification assay. To identify compounds that oxidize NADPH, we screened the formation of hydrogen peroxide (H O ) in the absence of UGM using the xylenol orange assay as previously 2 2 reported . The assay was performed in 384 well plates (Greiner, 781162) and the reaction volume was 15 μL and consisted of 50 mM HEPES buffer (pH 7.5) containing 200 mM NaCl, 500 µ M NADPH, and 200 µ M of compound (dissolved in DMSO). The final DMSO concentration in the reaction mix was 2%. Controls contained 2% DMSO instead of compound. The reaction was started by the addition of NADPH and allowed to proceed at room tem- perature in the dark. Ae ft r 45 min, the reaction was quenched with 85 µ L of a freshly made solution of 200 mM sorbitol, 250 µ M xylenol orange, 500 µ M ammonium ferrous sulfate, and 25 mM sulfuric acid. Aer 10 ft minutes of incubation, the absorbance was measured at 595 nm. The concentration of H O in samples was determined by 2 2 comparison with a predetermined H O standard curve containing 2% DMSO. 2 2 ThermoFAD assays. The melting temperature of UGM was determined by measuring the FAD fluores- cence as a function of temperature (20–90 °C, 1 °C step) following the reported ThermoFAD procedure . The reaction mix consisted of 20 µ L of 1 mg/mL UGM, 2% DMSO in 50 mM potassium phosphate buffer, pH 7.0. As a reference and positive control, the T was calculated in the presence DMSO and UDP (10 mM). Different concentrations of inhibitors were added in the range of 0–1 mM at a final DMSO concentration of 2% in the above-mentioned buffer. All experiments were done in triplicate. Activity assay, IC , and K determination. e ac Th tivity of UGM and IC was determined by monitoring 50 i 50 the formation of UDP-Galp from UDP-Galf at 262 nm in a UPLC system. A 30 µ L reaction containing 25 mM HEPES buffer with 125 mM NaCl, 20 µ M UDP-Galf, 10 mM sodium dithionite, 10 nM UGM (concentration based on FAD), 2% DMSO, and inhibitor (0–1 mM) were incubated at 25 °C for 3 min. Protein and inhibitor were pre-incubated for 5 min at 25 °C in reaction buffer (25 mM HEPES containing 125 mM NaCl) and the reaction was started with the addition of 3 µL of 200 µM UDP-Galf. The reaction was quenched with the addition of 70 µL acetonitrile. After removing the protein by centrifugation, 5 µ L of sample was injected into an Amide column (Acquity UPLC BEH Amide, 1.7 µ m, 2.1 mm × 100 mm) at 45 °C. The UPLC column was pre-equilibrated with 75% acetonitrile and 25% 27 mM aqueous HPLC-grade potassium phosphate (pH 4.5). Samples were run at a flow rate of 0.5 mL/min for 5 min. IC was also determined by following NADPH oxidation at 340 nm. The reaction mix consisted of 250 µ M NADPH, 25 mM HEPES with 125 mM NaCl, 2.5 µ M UGM, 2% DMSO, and inhibitor (0–1 mM). Data was analyzed using KaleidaGraph software. The type of inhibition was assessed by spectropho- tometrically (340 nm) recording the oxidation of various concentrations of NADPH (0–1 mM) in 25 mM HEPES containing 125 mM NaCl with 2.5 µ M UGM (based on FAD) at different concentrations of inhibitor with 2% DMSO in the absence of UDP-Galf. Global t fi ting was performed with Graphpad Prims 6 software (La Jolla, CA). ITC measurement. Binding of inhibitors to UGM was measured with an Auto-ITC 200 ITC instrument. UGM was dialyzed in 50 mM potassium phosphate bue ff r, pH 7.0, for 2 h at 4 °C. In all cases, ligands were dis- solved in dialysis buffer and protein and ligand were filtered with a 0.2 µ M membrane prior to loading. UGM concentration was 46 µ M in all titrations and the concentrations of NADP and UDP in the syringe were 16.8 mM and 400 µ M, respectively. Inhibitor concentration in the syringe was 2 mM (2% DMSO), except for chrysin where the concentration was 600 µ M (4% DMSO). Titration was performed in 16 injections of 2.5 µ L with spacing of 180S at 25 °C with continuous stirring at 750 rpm. Thermodynamic parameters were determined from ITC results using Microcal Origin version 7.0 (OriginLab) with the “ITC custom” add-on installed. Effect of (2S )-hesperetin and (2S)-naringenin on A. fumigatus growth. Spores of A. fumigatus from ATCC were germinated in potato dextrose agar (PDA). Spores were harvested using a sterile plastic scraper from 3 day old cultures grown at 37 °C and suspended in phosphate saline buffer containing 0.1% Tween-20. Inhibitor effect on cell growth was tested in 12-well plates (Falcon, 353043) containing 700 µ L agar at a final DMSO concentration of 1% and spot inoculated with 1 × 10 spores. For the toxicity studies, complete medium PDA containing 100–1000 µ M of inhibitor was spot inoculated with 1 × 10 spores and incubated at 37 °C. A control was inoculated into PDA with DMSO. Inhibitor or DMSO was mixed with the PDA agar before solidi- fying. For congo red susceptibly assays, inhibitors at 100 µ M concentration were added to aspergillus minimum media (AMM) containing congo red (1.0 and 0.5 mg/mL) before the agar jellified. The working concentrations 39 3 of congo red were determined by a serial dilution method in a 12-well plate inoculated with 1 × 10 spores and grown at 37 °C for 48 h. As the negative control, inoculated agar containing either congo red or 100 µM inhibitor were employed. For the thermotolerance studies, PDA medium containing 1000 µM of inhibitor was spot inocu- 3 5 lated with 1 × 10 and 1 × 10 spores and incubated at 50 °C for 48 h. As control, agar with DMSO was employed. SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 8 www.nature.com/scientificreports/ References 1. Latgé, J.-P. Aspergillus fumigatus and Aspergillosis. Clin. Microbiol. Rev. 12, 310–350 (1999). 2. Reece, E. et al. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic b fi rosis patients: an Irish registry analysis. BMC Pulm. Med. 17, 70; doi:10.1186/s12890-017-0416-4 (2017). 3. Low, C.-Y. & Rotstein, C. Emerging fungal infections in immunocompromised patients. F1000 Med. Rep. 3, 14; doi:10.3410/M3-14 (2011). 4. Taccone, F. S. et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Cri. Care 19, 7; doi:10.1186/s13054-014-0722-7 (2015). 5. Latgé, J.-P. Tasting the fungal cell wall. Cell. Microbiol. 12, 863–872 (2010). 6. Latgé, J.-P. & Beauvais, A. Functional duality of the cell wall. Curr. Opin. Microbiol. 20, 111–117 (2014). 7. Stynen, D. et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect. Immun. 60, 2237–2245 (1992). 8. Barreto-Bergter, E. & Figueiredo, R. T. Fungal glycans and the innate immune recognition. Front. Cell. Infect. Microbiol. 4, 145; doi:10.3389/fcimb.2014.00145 (2014). 9. Latgé, J.-P. Galactofuranose containing molecules in Aspergillus fumigatus. Med. Mycol. 47, S104–S109; doi:10.1080/13693780802258832 (2009). 10. Latgé, J. P. et al. Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect. Immun. 62, 5424–5433 (1994). 11. Leitão, E. A. et al. β-Galactofuranose-containing O-linked oligosaccharides present in the cell wall peptidogalactomannan of Aspergillus fumigatus contain immunodominant epitopes. Glycobiology 13, 681–692 (2003). 12. Schmalhorst, P. S. et al. Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus. Eukaryotic Cell 7, 1268–1277 (2008). 13. Pan, F., Jackson, M., Ma, Y. & McNeil, M. Cell wall core galactofuran synthesis is essential for growth of Mycobacteria. J. Bacteriol. 183, 3991–3998 (2001). 14. Kumar, S. et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS One 2, e1189; doi:10.1371/ journal.pone.0001189 (2007). 15. Latha, A. A. & Narayanan, R. B. UDP-galactopyranose mutase as a possible drug target for the human filarial parasite, Brugia malayi : an in silico evaluation. Int. J. Med. Eng. Inf. 5, 372–382 (2013). 16. Novelli, J. F. et al. Characterization of the Caenorhabditis elegans UDP-galactopyranose mutase homolog glf-1 reveals an essential role for galactofuranose metabolism in nematode surface coat synthesis. Dev. Biol. 335, 340–355 (2009). 17. Kleczka, B. et al. Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J. Biol. Chem. 282, 10498–10505 (2007). 18. Oppenheimer, M., Poulin, M. B., Lowary, T. L., Helm, R. F. & Sobrado, P. Characterization of recombinant UDP-galactopyranose mutase from Aspergillus fumigatus. Arch. Biochem. Biophys. 502, 31–38 (2010). 19. Mehra-Chaudhary, R., Dai, Y., Sobrado, P. & Tanner, J. J. In crystallo capture of a covalent intermediate in the UDP-galactopyranose mutase reaction. Biochemistry 55, 833–836 (2016). 20. Oppenheimer, M., Valenciano, A. L., Kizjakina, K., Qi, J. & Sobrado, P. Chemical mechanism of UDP-galactopyranose mutase from Trypanosoma cruzi: a potential drug target against Chagas’ disease. PLoS One 7, e32918; doi:10.1371/journal.pone.0032918 (2012). 21. Dhatwalia, R. et al. Identification of the NAD(P)H binding site of eukaryotic UDP-galactopyranose mutase. J. Am. Chem. Soc. 134, 18132–18138 (2012). 22. Qi, J., Kizjakina, K., Robinson, R., Tolani, K. & Sobrado, P. A fluorescence polarization binding assay to identify inhibitors of flavin- dependent monooxygenases. Anal. Biochem. 425, 80–87 (2012). 23. Feng, B. Y. & Shoichet, B. K. A Detergent-based assay for the detection of promiscuous Inhibitors. Nat. Protoc. 1, 550–553 (2006). 24. Thorne, N., Auld, D. S. & Inglese, J. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315–324 (2010). 25. Sucharitakul, J., Prongjit, M., Haltrich, D. & Chaiyen, P. Detection of a C4a-hydroperoxyflavin intermediate in the reaction of a flavoprotein oxidase. Biochemistry 47, 8485–8490 (2008). 26. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49, 7274–7277 (2006). 27. Valiante, V., Macheleidt, J., Föge, M. & Brakhage, A. A. The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Front. Microbiol. 6, 325; doi:10.3389/fmicb.2015.00325 (2015). 28. Ghannoum, M. A. & Rice, L. B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12, 501–517 (1999). 29. Vincent, S. et al. Natural and synthetic flavonoids as potent Mycobacterium tuberculosis UGM inhibitors. Chem. - Eur. J. 23, 10423–10429 (2017). 30. Peltier , P . et al. Synthetic UDP-furanoses as potent inhibitors of mycobacterial galactan biogenesis. Chem. Biol. 17, 1356–1366 (2010). 31. Frédéric, C. J. M. et al. Synthesis of unprecedented sulfonylated phosphono-exo-glycals designed as inhibitors of the three Mycobacterial galactofuranose processing enzymes. Chem. – Eur. J. 22, 15913–15920 (2016). 32. Choi, E. M. & Lee, Y. S. Effects of hesperetin on the production of inflammatory mediators in IL-1beta treated human synovial cells. Cell. Immunol. 264, 1–3 (2010). 33. Bai, X. et al. The protective effect of the natural compound hesperetin against fulminant hepatitis in vivo and in vitro. Br. J. Pharmacol. 174, 41–56 (2017). 34. Zhu, C., Dong, Y., Liu, H., Ren, H. & Cui, Z. Hesperetin protects against H O -triggered oxidative damage via upregulation of the 2 2 Keap1-Nrf2/HO-1 signal pathway in ARPE-19 cells. Biomed. Pharmacother. 88, 124–133 (2017). 35. Liu, D. et al. Inhibitory effect of hesperetin and naringenin on human UDP-glucuronosyltransferase enzymes: implications for herb–drug interactions. Biol. Pharm. Bull. 39, 2052–2059 (2016). 36. Lopes, L. A. A., dos S Rodrigues, J. B., Magnani, M., de Souza, E. L. & de Siqueira-Júnior, J. P. Inhibitory effects of flavonoids on biofilm formation by Staphylococcus aureus that overexpresses efflux protein genes. Microb. Pathog. 107, 193–197 (2017). 37. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13, 869–874 (2008). 38. Chodera, J. D. & Mobley, D. L. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu. Rev. Biophys. 42, 121–142 (2013). 39. Ram, A. F. J. & Klis, F. M. Identification of fungal cell wall mutants using susceptibility assays based on calcouo fl r white and congo red. Nat. Protoc. 1, 2253–2256 (2006). 40. Martín del Campo, J. S. et al. Inhibition of the flavin-dependent monooxygenase siderophore A (SidA) blocks siderophore biosynthesis and Aspergillus fumigatus growth. ACS Chem. Biol. 11, 3035–3042 (2016). 41. Forneris, F., Orru, R., Bonivento, D., Chiarelli, L. R. & Mattevi, A. ThermoFAD, a Thermouo fl r -adapted flavin ad hoc detection system for protein folding and ligand binding. FEBS J. 276, 2833–2840 (2009). 42. Schrettl, M. et al. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J. Exp. Med. 200, 1213–1219 (2004). SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 9 www.nature.com/scientificreports/ Acknowledgements This work was supported by a National Institutes of Health Grant GM094469 and funds from the Fralin Life Science Institute. We are grateful to Dr. Karina Kizjakina for synthesizing and purifying the UDP-Galf. Author Contributions J.S.M.C. wrote the main manuscript, performed H.T.S., inhibition, cell assays, and data analysis. M.E. performed I.T.C. measurements and prepared I.T.C. figures. N.V. optimized and performed the H.T.S. assay. P.S. supervised the project and wrote the manuscript. All authors reviewed the manuscript. Additional Information Supplementary information accompanies this paper at doi:10.1038/s41598-017-11022-5 Competing Interests: The authors declare that they have no competing interests. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre- ative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not per- mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2017 SCienTifiC Repo R ts | 7: 10836 | DOI:10.1038/s41598-017-11022-5 10

Journal

Scientific ReportsSpringer Journals

Published: Sep 7, 2017

There are no references for this article.